News & Events Upcoming events Sep 21, 2026 - Sep 23, 2026 International Congress on Neurodegenerative Diseases - ICND 2026 Sevilla, Spain More info and meet us there Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there Nov 16, 2026 - Nov 19, 2026 MEDICA 2026 Düsseldorf, Germany More info and meet us there See all upcoming events Latest news Dec 17, 2019 Fujirebio Diagnostics Announces FDA Clearance of Lumipulse® G CA19-9-N Assay Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G1200 CA19-9-N assay for testing on its LUMIPULSE® G1200 immunoassay platform. Read more Oct 29, 2019 Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G whole PTH Assay A 3rd Generation Assay to Accurately Measure Biologically Active Parathyroid Hormone Levels Resulting From Disorders of Calcium Metabolism Read more Feb 14, 2019 Fujirebio Diagnostics Receives FDA Breakthrough Device Designation for Lumipulse® G β-Amyloid Ratio (1-42/1-40) Quantitative In Vitro Diagnostic Test Read more Jun 11, 2018 Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay Read more May 1, 2018 Fujirebio enters into agreement with Janssen Pharmaceuticals to develop and commercialize AMYLOID β 42/40 RATIO assay Read more Sep 4, 2017 Morphotek®, Inc. Announces an Agreement With Fujirebio Diagnostics, Inc to commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab® Read more Load More
Sep 21, 2026 - Sep 23, 2026 International Congress on Neurodegenerative Diseases - ICND 2026 Sevilla, Spain More info and meet us there
Oct 21, 2026 - Oct 23, 2026 MSToronto 2026 - 10th Joint ACTRIMS-ECTRIMS Meeting Toronto, Canada More info and meet us there
Dec 17, 2019 Fujirebio Diagnostics Announces FDA Clearance of Lumipulse® G CA19-9-N Assay Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G1200 CA19-9-N assay for testing on its LUMIPULSE® G1200 immunoassay platform. Read more
Oct 29, 2019 Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G whole PTH Assay A 3rd Generation Assay to Accurately Measure Biologically Active Parathyroid Hormone Levels Resulting From Disorders of Calcium Metabolism Read more
Feb 14, 2019 Fujirebio Diagnostics Receives FDA Breakthrough Device Designation for Lumipulse® G β-Amyloid Ratio (1-42/1-40) Quantitative In Vitro Diagnostic Test Read more
Jun 11, 2018 Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G B•R•A•H•M•S PCT Assay Read more
May 1, 2018 Fujirebio enters into agreement with Janssen Pharmaceuticals to develop and commercialize AMYLOID β 42/40 RATIO assay Read more
Sep 4, 2017 Morphotek®, Inc. Announces an Agreement With Fujirebio Diagnostics, Inc to commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab® Read more
